Pierrel Logo

Pierrel

Pharmaceutical firm specializing in dental anesthetics and contract manufacturing.

PRL | XMIL

Overview

Corporate Details

ISIN(s):
IT0005549644
LEI:
8156002BC7CB6E3BD403
Country:
Italy
Address:
STRADA STATALE APPIA 7 BIS, 46/48, 81043 CAPUA

Description

Pierrel is a global pharmaceutical company specializing in oral health. With over 70 years of experience, the company focuses on the development, production, registration, and licensing of dental anesthetics and complementary medical devices. Its core expertise lies in the aseptic manufacturing of injectable drugs. The product portfolio includes a wide range of dental anesthetics marketed under its own brands, such as Orabloc®, Ubisestin™, Xylestesin™, and Mepivastesin™. In addition to its branded products, Pierrel offers medical devices for oral pathology screening, prevention, and regeneration. The company also provides contract manufacturing services to the pharmaceutical and life science industries. Its production facilities are authorized by major global regulatory agencies, including the EMA and FDA, ensuring compliance with high international quality standards.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2024-01-24 12:25
Pierrel S.p.A.: OFFERTA PUBBLICA DI ACQUISTO VOLONTARIA TOTALITARIA SULLE AZION…
Italian 249.0 KB
2024-01-17 19:37
Pierrel S.p.A.: OFFERTA PUBBLICA DI ACQUISTO VOLONTARIA TOTALITARIA SULLE AZION…
Italian 262.6 KB
2023-12-20 20:07
Pierrel S.p.A.: Comunicato ai sensi dell’art. 41, co. 6 RE, emesso da PRL S.p.A…
Italian 261.4 KB
2023-12-15 21:19
Pierrel S.p.A.: Comunicato ai sensi dell’art. 36 del RE, emesso da PRL SpA
Italian 230.9 KB
2023-12-14 20:16
Pierrel S.p.A.: Comunicato ai sensi degli artt. 36 e 43 del Regolamento adottat…
Italian 227.0 KB
2023-11-29 11:28
Pierrel S.p.A.: Bilancio d'esercizio al 31.12.2022
Italian 4.9 MB
2023-11-28 21:23
Pierrel S.p.A.: Comunicato ai sensi dell’art. 36 del RE - emesso da PRL S.p.A. …
Italian 242.8 KB
2023-11-24 23:43
Pierrel S.p.A.: Comunicato ai sensi dell’art. 38, co. 2 RE,emesso da PRL S.p.A.…
Italian 221.8 KB
2023-11-24 19:28
Pierrel S.p.A.: IL CDA DI PIERREL APPROVA IL COMUNICATO DELL’EMITTENTE IN REL. …
Italian 256.7 KB
2023-11-22 22:55
Pierrel S.p.A.: PRL S.p.A. OFFERTA PUBBLICA DI ACQUISTO VOLONTARIA TOTALITARIA …
Italian 203.6 KB
2023-11-16 15:43
Pierrel S.p.A.: Informazioni essenziali Addendum al patto parasociale – 16 nove…
Italian 310.4 KB
2023-11-16 15:40
Pierrel S.p.A.: Estratto Addendum al patto parasociale – 16 novembre 2023
Italian 1.2 MB
2023-11-15 11:03
Pierrel S.p.A.: Comunicato ai sensi dell’art. 38, co. 1, del Regolamento - AVVI…
Italian 133.7 KB
2023-10-31 17:18
Pierrel S.p.A.: Comunicato ai sensi dell’art. 38, co. 1,emesso da PRL S.p.A. e …
Italian 141.2 KB
2023-10-24 11:11
Pierrel S.p.A.: Comunicato ai sensi dell’art. 102, comma 3, del D.Lgs. 24 febbr…
Italian 215.6 KB

Automate Your Workflow. Get a real-time feed of all Pierrel filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Pierrel

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Pierrel via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Acurx Pharmaceuticals, Inc. Logo
Clinical-stage biopharma developing a new class of antibiotics for priority pathogens.
United States of America
ACXP
Adaptimmune Therapeutics PLC Logo
Commercial-stage biopharma developing TCR T-cell therapies for solid tumors.
United States of America
ADAP
ADBIOTECH Co.,Ltd. Logo
Develops IgY-based immune antibodies as alternatives to vaccines and antibiotics.
South Korea
179530
ADC Therapeutics SA Logo
Commercial-stage biotech developing antibody-drug conjugates for cancer therapy.
United States of America
ADCT
Addex Therapeutics Ltd. Logo
Clinical-stage biopharma developing allosteric modulators for neurological disorders.
Switzerland
ADXN
ADIAL PHARMACEUTICALS, INC. Logo
A clinical-stage biopharma developing genetically targeted therapies for addiction.
United States of America
ADIL
Adicet Bio, Inc. Logo
Develops allogeneic gamma delta T cell therapies for cancer and autoimmune diseases.
United States of America
ACET
Adlai Nortye Ltd. Logo
A clinical-stage biopharma firm developing cancer immunotherapies and RAS-targeting drugs.
United States of America
ANL
ADMA BIOLOGICS, INC. Logo
Biopharmaceutical company that develops and manufactures plasma-derived biologics.
United States of America
ADMA
Adverum Biotechnologies, Inc. Logo
A clinical-stage company developing gene therapies for ocular diseases.
United States of America
ADVM

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.